Other languages VACCINEXPAR

Equities

VCNX

US9186403013

Market Closed - Nasdaq Other stock markets 02:00:00 02/05/2024 am IST			5-day change	1st Jan Change
6 ^USD	+1.01%		+19.88%	-35.53%

12/04	Vaccinex, Inc. announced that it has received $1.75 million in funding	CI
02/04	Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vaccinex, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02/04
Vaccinex, Inc. Announces Executive Changes, Effective March 14, 2024	05/03
Sector Update: Health Care Stocks Slipping Wednesday Afternoon	22/02
Vaccinex Shares Rise as Company Announces Eight New Deals for Antibody Discovery Platform	21/02
Vaccinex, Inc. Announces Multiple New Agreements for Access to ActivMAb Antigen Virus Technology	21/02
Vaccinex, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Vaccinex, Inc. Reports Clinical Benefit in Interim Analyses from Two Phase 2 Studies of Pepinemab Combination Treatment At Society for Immunotherapy of Cancer's Annual Meeting	31/23/31
Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases	26/23/26
Top Premarket Gainers	06/23/06
Vaccinex Insider Bought Shares Worth $3,000,000, According to a Recent SEC Filing	06/23/06
Vaccinex Insider Bought Shares Worth $509,515, According to a Recent SEC Filing	06/23/06
Top Midday Decliners	29/23/29
Wall Street Set to Open Higher; Personal Consumption Inflation Data Lower Than Expected	29/23/29
Top Premarket Decliners	29/23/29
Vaccinex Prices Offering of Shares, Warrants for Gross Proceeds of About $9.6 Million	29/23/29
Vaccinex's Next Generation ActivMAb®? Technology Published in mAbs	28/23/28
Vaccinex, Inc. to Present Update on PDAC/Pepinemab Study	27/23/27
Vaccinex Reports Groundbreaking Findings At Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer	26/23/26
MORNING BRIEFING - USA/Asien	25/23/25
Vaccinex to Implement 1-for-15 Reverse Stock Split	23/23/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages VACCINEXPAR

Equities

VCNX

US9186403013

Other languages

Filters